Zanamivir and oseltamivir are influenza antiviral drugs that inhibit the viral neuraminidase enzyme, preventing release and spread of the virus. They reduce the duration of influenza A and B symptoms if taken within 48 hours of onset, and can prevent infection in close contacts. Oseltamivir is not recommended for infants under 1 year old due to fatalities seen in mice, and zanamivir may cause bronchospasms in those with asthma or lung disease.
Zanamivir and oseltamivir are influenza antiviral drugs that inhibit the viral neuraminidase enzyme, preventing release and spread of the virus. They reduce the duration of influenza A and B symptoms if taken within 48 hours of onset, and can prevent infection in close contacts. Oseltamivir is not recommended for infants under 1 year old due to fatalities seen in mice, and zanamivir may cause bronchospasms in those with asthma or lung disease.
Zanamivir and oseltamivir are influenza antiviral drugs that inhibit the viral neuraminidase enzyme, preventing release and spread of the virus. They reduce the duration of influenza A and B symptoms if taken within 48 hours of onset, and can prevent infection in close contacts. Oseltamivir is not recommended for infants under 1 year old due to fatalities seen in mice, and zanamivir may cause bronchospasms in those with asthma or lung disease.
Zanamivir and oseltamivir are influenza antiviral drugs that inhibit the viral neuraminidase enzyme, preventing release and spread of the virus. They reduce the duration of influenza A and B symptoms if taken within 48 hours of onset, and can prevent infection in close contacts. Oseltamivir is not recommended for infants under 1 year old due to fatalities seen in mice, and zanamivir may cause bronchospasms in those with asthma or lung disease.
Mechanism of action Zanamivir and oseltamivir inhibit viral neuraminidase, an enzyme essential for release of newly formed virus particles from infected cells and further spread of the infectious virus. Clinical use Zanamivir and oseltamivir are effective for reducing the duration of influenza A and B if administered within 48 hours of symptom onset and may prevent viral infection in close contacts of affected individuals. Adverse effects Oseltamivir is not recommended in infants younger than 1 year because of fatalities in mice. Zanamivir should be avoided in those with asthma or chronic obstructive pulmonary disease because it can cause bronchospasm